Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_assertion type Assertion NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_head.
- NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_assertion description "[The system contains: (1) nanostructured lipid carriers (NLC); (2) anticancer drug (doxorubicin or paclitaxel); (3) siRNA targeted to MRP1 mRNA as a suppressor of pump drug resistance; (4) siRNA targeted to BCL2 mRNA as a suppressor of nonpump cellular resistance and (5) a modified synthetic analog of luteinizing hormone-releasing hormone (LHRH) as a targeting moiety specific to the receptors that are overexpressed in the plasma membrane of lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_provenance.
- NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_assertion evidence source_evidence_literature NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_provenance.
- NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_assertion SIO_000772 23648833 NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_provenance.
- NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_assertion wasDerivedFrom befree-20150227 NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_provenance.
- NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_assertion wasGeneratedBy ECO_0000203 NP569386.RAehxmU-n7-7s_xLpLN8lPfAKYl94K7pKBu7eciPvsC-Q130_provenance.